Beijing Foyou Pharma Co., Ltd.SSE: 601089

Announcement on Convening the Q1 2026 Performance Briefing

Apr 22, 2026 · Issued by Beijing Foyou Pharma Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 22, 2026

On 6ix: 6ix.com/news/announcement-on-convening-the-q1-2026-performance-briefing-33

Announcement on Convening the Q1 2026 Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Beijing Foyou Pharma Co., Ltd. on 6ix

Earlier from Beijing Foyou Pharma

Announcement on Obtaining Drug Registration Certificate for Pioglitazone-Metformin Tablets (I)Apr 21
Announcement on 2025 Annual Profit Distribution PlanApr 14
Announcement on Obtaining Drug Registration Certificate for Dibutyrosine Adenosyl Methyltransferase Enteric-coated TabletsApr 8
Announcement on Obtaining the Notice of Approval for Drug Clinical Trials of Bimatoprost OintmentApr 1
Announcement on Subsidiary's Passing GMP Compliance InspectionMar 31

Later from Beijing Foyou Pharma

Announcement on Obtaining Approval for Marketing of Chemical APIsApr 24
Report for Q1 2026Apr 25
Announcement on Obtaining Drug Registration Certificate for Olmesartan Medoxomil Orally Disintegrating TabletsMay 8
Announcement on Obtaining Drug Registration Certificate for Clopidogrel Aspirin TabletsMay 22
Announcement on Implementation of Dividend Distribution for 2025May 27

All Beijing Foyou Pharma news releases

Follow Beijing Foyou Pharma into a list and get an email when it puts out news.

Follow Beijing Foyou Pharma